PubRank

U Helena Danielson

Author PubWeight™ 43.35‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. J Virol 2009 1.17
2 Structural basis of ligand recognition in 5-HT3 receptors. EMBO Rep 2012 0.96
3 Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. J Med Chem 2002 0.95
4 Effects on protease inhibition by modifying of helicase residues in hepatitis C virus nonstructural protein 3. FEBS J 2007 0.92
5 Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands. J Med Chem 2010 0.91
6 Kinetic and thermodynamic characterization of HIV-1 protease inhibitors. J Mol Recognit 2004 0.91
7 Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J Med Chem 2006 0.90
8 Characterization of Ca2+ and phosphocholine interactions with C-reactive protein using a surface plasmon resonance biosensor. Anal Biochem 2009 0.89
9 Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. J Med Chem 2011 0.89
10 Interaction kinetic characterization of HIV-1 reverse transcriptase non-nucleoside inhibitor resistance. J Med Chem 2006 0.86
11 Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. J Med Chem 2008 0.86
12 Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3. Antivir Ther 2007 0.85
13 Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-Length NS3 (protease-helicase/NTPase): a comparative study of different C-terminals. Bioorg Med Chem 2003 0.84
14 On the active site protonation state in aspartic proteases: implications for drug design. Curr Pharm Des 2013 0.84
15 Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants. Antiviral Res 2003 0.83
16 Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. J Med Chem 2011 0.83
17 Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. Biochemistry 2010 0.83
18 Interaction kinetic and structural dynamic analysis of ligand binding to acetylcholine-binding protein. Biochemistry 2010 0.82
19 Quantification of interactions between drug leads and serum proteins by use of "binding efficiency". Anal Biochem 2010 0.82
20 Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Res 2013 0.82
21 HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases. Biochem Biophys Res Commun 2002 0.81
22 Structure-activity relationships of HCV NS3 protease inhibitors evaluated on the drug-resistant variants A156T and D168V. Antivir Ther 2010 0.81
23 Characterization of Ca2+ interactions with matrix metallopeptidase-12: implications for matrix metallopeptidase regulation. Biochem J 2006 0.80
24 Biosensor-based screening and characterization of HIV-1 inhibitor interactions with Sap 1, Sap 2, and Sap 3 from Candida albicans. J Biomol Screen 2006 0.80
25 Identification of structural-kinetic and structural-thermodynamic relationships for thrombin inhibitors. Biochemistry 2013 0.80
26 Biomolecular recognition of glycosylated beta(3)-peptides by GalNAc specific lectins. J Mol Recognit 2007 0.80
27 Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data. J Med Chem 2004 0.80
28 Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. Bioorg Med Chem 2005 0.80
29 Kinetic and mechanistic analysis of the association and dissociation of inhibitors interacting with secreted aspartic acid proteases 1 and 2 from Candida albicans. Biochim Biophys Acta 2003 0.79
30 Biotinylated lipid bilayer disks as model membranes for biosensor analyses. Anal Biochem 2010 0.79
31 Sensitivity analysis and error structure of progress curves. Anal Biochem 2006 0.79
32 A surface plasmon resonance-based biosensor with full-length BACE1 in a reconstituted membrane. Anal Biochem 2011 0.78
33 Powerful protein binders from designed polypeptides and small organic molecules--a general concept for protein recognition. Angew Chem Int Ed Engl 2011 0.78
34 Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety. Bioorg Med Chem 2007 0.78
35 Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. J Med Chem 2013 0.78
36 Early absorption and distribution analysis of antitumor and anti-AIDS drugs: lipid membrane and plasma protein interactions. J Med Chem 2005 0.78
37 Studies of substrate-induced conformational changes in human cytomegalovirus protease using optical biosensor technology. Anal Biochem 2004 0.78
38 Development of surface plasmon resonance biosensor assays for primary and secondary screening of acetylcholine binding protein ligands. Anal Biochem 2010 0.78
39 Histaminergic pharmacology of homo-oligomeric β3 γ-aminobutyric acid type A receptors characterized by surface plasmon resonance biosensor technology. Biochem Pharmacol 2012 0.78
40 Kinetic and mechanistic differences in the interactions between caldendrin and calmodulin with AKAP79 suggest different roles in synaptic function. J Mol Recognit 2012 0.77
41 Analysis of the pH-dependencies of the association and dissociation kinetics of HIV-1 protease inhibitors. J Mol Recognit 2003 0.77
42 Refolding of a recombinant full-length non-structural (NS3) protein from hepatitis C virus by chromatographic procedures. Biotechnol Lett 2003 0.77
43 Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors. Bioorg Med Chem 2003 0.77
44 Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents. Bioorg Med Chem 2010 0.77
45 Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol 2010 0.77
46 Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors. Biochemistry 2009 0.77
47 The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. J Med Chem 2013 0.76
48 Experimental validation of a fragment library for lead discovery using SPR biosensor technology. J Biomol Screen 2010 0.76
49 HSA binding of HIV protease inhibitors: a high-performance affinity chromatography study. J Sep Sci 2009 0.76
50 Screening for NNRTIs with slow dissociation and high affinity for a panel of HIV-1 RT variants. J Biomol Screen 2009 0.76
51 Expression and purification of recombinant full-length NS3 protease-helicase from a new variant of Hepatitis C virus. Protein Expr Purif 2002 0.76
52 Aliskiren displays long-lasting interactions with human renin. Naunyn Schmiedebergs Arch Pharmacol 2011 0.76
53 Efficient screening of marine extracts for protease inhibitors by combining FRET based activity assays and surface plasmon resonance spectroscopy based binding assays. Mar Drugs 2013 0.75
54 Tetrapeptides as potent protease inhibitors of Hepatitis C Virus full-length NS3 (protease-helicase/NTPase). Bioorg Med Chem 2002 0.75
55 Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones. Bioorg Med Chem 2010 0.75
56 Structure-activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors. Biochim Biophys Acta 2004 0.75
57 Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket. J Med Chem 2013 0.75
58 Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors. J Enzyme Inhib Med Chem 2014 0.75
59 Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Bioorg Med Chem 2007 0.75
60 Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles. Bioorg Med Chem 2014 0.75
61 Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis. Bioorg Med Chem 2007 0.75
62 Detection of competitive enzyme inhibition with end point progress curve data. Anal Biochem 2006 0.75
63 Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants. J Med Chem 2014 0.75
64 P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis. Bioorg Med Chem 2011 0.75
65 Refolding of the full-length non-structural protein 3 of hepatitis C virus. Protein Expr Purif 2005 0.75
66 Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors. J Mol Recognit 2011 0.75
67 Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3. J Enzyme Inhib Med Chem 2007 0.75